These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 1666824)
1. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program. Andries K; Dewindt B; Snoeks J; Willebrords R; Stokbroekx R; Lewi PJ Antiviral Res; 1991 Oct; 16(3):213-25. PubMed ID: 1666824 [TBL] [Abstract][Full Text] [Related]
2. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. Andries K; Dewindt B; Snoeks J; Wouters L; Moereels H; Lewi PJ; Janssen PA J Virol; 1990 Mar; 64(3):1117-23. PubMed ID: 2154596 [TBL] [Abstract][Full Text] [Related]
3. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses. Dewindt B; van Eemeren K; Andries K Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059 [TBL] [Abstract][Full Text] [Related]
4. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887 [TBL] [Abstract][Full Text] [Related]
5. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14. Fox MP; McKinlay MA; Diana GD; Dutko FJ Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851 [TBL] [Abstract][Full Text] [Related]
6. Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A. Mallamo JP; Diana GD; Pevear DC; Dutko FJ; Chapman MS; Kim KH; Minor I; Oliveira M; Rossmann MG J Med Chem; 1992 Dec; 35(25):4690-5. PubMed ID: 1335081 [TBL] [Abstract][Full Text] [Related]
7. A novel basis of capsid stabilization by antiviral compounds. Phelps DK; Post CB J Mol Biol; 1995 Dec; 254(4):544-51. PubMed ID: 7500332 [TBL] [Abstract][Full Text] [Related]
8. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides. Ninomiya Y; Shimma N; Ishitsuka H Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796 [TBL] [Abstract][Full Text] [Related]
10. A model for compounds active against human rhinovirus-14 based on X-ray crystallography data. Diana GD; Treasurywala AM; Bailey TR; Oglesby RC; Pevear DC; Dutko FJ J Med Chem; 1990 May; 33(5):1306-11. PubMed ID: 2158559 [TBL] [Abstract][Full Text] [Related]
11. Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules. Shih SR; Chen SJ; Hakimelahi GH; Liu HJ; Tseng CT; Shia KS Med Res Rev; 2004 Jul; 24(4):449-74. PubMed ID: 15170592 [TBL] [Abstract][Full Text] [Related]
12. Structure-based drug design of antirhinoviral compounds. Giranda VL Structure; 1994 Aug; 2(8):695-8. PubMed ID: 7994569 [TBL] [Abstract][Full Text] [Related]
13. VP4 protein from human rhinovirus 14 is released by pressure and locked in the capsid by the antiviral compound WIN. Gonçalves RB; Mendes YS; Soares MR; Katpally U; Smith TJ; Silva JL; Oliveira AC J Mol Biol; 2007 Feb; 366(1):295-306. PubMed ID: 17161425 [TBL] [Abstract][Full Text] [Related]
14. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Rozhon E; Cox S; Buontempo P; O'Connell J; Slater W; De Martino J; Schwartz J; Miller G; Arnold E; Zhang A Antiviral Res; 1993 May; 21(1):15-35. PubMed ID: 8391247 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Andries K; Dewindt B; Snoeks J; Willebrords R; van Eemeren K; Stokbroekx R; Janssen PA Antimicrob Agents Chemother; 1992 Jan; 36(1):100-7. PubMed ID: 1317142 [TBL] [Abstract][Full Text] [Related]
16. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization. Andries K; Dewindt B; Snoeks J; Willebrords R Arch Virol; 1989; 106(1-2):51-61. PubMed ID: 2548460 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and antirhinovirus activity of 3-(diethylamino)-5-phenylisoxazole derivatives. Mazzei M; Garzoglio R; Balbi A; Grandi T; De Montis A; Corrias S; La Colla P Farmaco; 1996 May; 51(5):351-9. PubMed ID: 8767845 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors. Conti C; Proietti Monaco L; Desideri N Bioorg Med Chem; 2011 Dec; 19(24):7357-64. PubMed ID: 22088306 [TBL] [Abstract][Full Text] [Related]
20. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Smith TJ; Kremer MJ; Luo M; Vriend G; Arnold E; Kamer G; Rossmann MG; McKinlay MA; Diana GD; Otto MJ Science; 1986 Sep; 233(4770):1286-93. PubMed ID: 3018924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]